Business
Ondine Biomedical announces AIM market listing
Ondine Biomedical announces AIM market listing.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n \n \n \n RNS Number : 5992U\n Ondine Biomedical Inc.\n 06 December 2021\n \n \n \n NOT FOR RELEASE, DISTRIBUTION, PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.\n \n \n Ondine Biomedical Inc.\n \n (\"Ondine Biomedical\" or the \"Company\")\n \n \n \n \n Ondine Biomedical announces AIM market listing\n \n \n \n \n Ondine Biomedical (OBI:AIM) announces admission (\"Admission\") of its Common Shares to the AIM Market of the London Stock Exchange. Canadian based Ondine has pioneered a new non-antibiotic antimicrobial technology called photodisinfection which rapidly destroys pathogens - including SARS-CoV-2 - without causing resistance.\n Application has been made for admission to trading on the AIM Market of the London Stock Exchange of 194,584,524 Common Shares. It is expected that admission will occur today at 8.00 a.m.\n \n \n For further Information, contact:\n \n \n Ondine Biomedical Inc.\n Carolyn Cross, CEO +1 604 669 0555\n \n Arden Partners plc\n Nominated Adviser and Broker +44 (0)20 7614 5900\n Ruari McGirr / Antonio Bossi\n \n Vane Percy & Roberts\n Financial PR\n Simon Vane Percy +44 (0) 1737 821891\n \n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.\n END\n \n AIMFSWEEIEFSEFE\n ","length":3468,"tagName":"div"}]